McKesson Increases Annual Profit Forecast and Sets Timeline for Medical-Surgical Unit IPO

McKesson Corporation MCK announced on February 5, 2026, that it has raised its fiscal 2026 adjusted earnings-per-share forecast, citing strong performance across its core business segments. The company now expects its adjusted earnings to range between $38.80 and $39.20 per share, up from the previously issued guidance of $38.35 to $38.85. This upward revision follows a quarterly report where the company exceeded analyst expectations for both revenue and adjusted earnings per share, according to data from LSEG.

The improved financial outlook is primarily driven by significant growth in the McKesson U.S. pharmaceutical unit. The company highlighted robust demand within its oncology and specialty drug distribution businesses as a key factor in the revision. As the largest pharmaceutical distributor in the US US, the company continues to benefit from its scale and positioning within the high-growth specialty medicines sector.